Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.
Gennaro Esposito(New York University Abu Dhabi), Marco Salvatore(Istituto Superiore di Sanità), N. Panza, Luigi Mansi(University of Naples Federico II), G Pacilio, A. De Matteis(Università Cattolica del Sacro Cuore), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Giuseppe D’Aiuto(Memorial Sloan Kettering Cancer Center), V. Labonia
PubMed
January 10, 1991
Cited by 3
Related Papers
Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
|JNCI Journal of the National Cancer Institute|2007|242
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108